Clinical Trials Logo

Breast Cancer clinical trials

View clinical trials related to Breast Cancer.

Filter by:

NCT ID: NCT06186011 Recruiting - Breast Cancer Clinical Trials

Quality of Life and Cosmetic Outcomes of Breast-Conserving Surgery According to Localization Method

TRIGUIDE
Start date: October 4, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare Quality of Life and cosmetic outcomes in Breast Conservative Carcer surgery depending on localization method (intraoperative Ultrasound, wire and radioactive seed). Participants will be randomly assigned to one of the three proposed arms, and the primary surgery will be performed.

NCT ID: NCT06185972 Not yet recruiting - Breast Cancer Clinical Trials

Novel Magnetic Resonance Imaging-Guided Ultrasound-Stimulated Microbubble Radiation Treatment for Patients With Chest-Wall and Locally Advanced Breast Cancer-Phase II

Start date: February 1, 2024
Phase: Phase 2
Study type: Interventional

The objective of this study is to demonstrate the efficacy and response of novel Magnetic Resonance Imaging (MRI)-guided ultrasound stimulated microbubble treatment to enhance radiation effects in humans receiving external beam radiotherapy delivered using a LINAC (linear accelerator) radiation therapy device.

NCT ID: NCT06185946 Recruiting - Clinical trials for Breast Carcinoma Metastatic in Lymph Node

Evaluation of Different Imaging Modalities in Regional Lymph Nodes Staging in Patients With Breast Cancer

Start date: January 1, 2024
Phase:
Study type: Observational

The regional lymph node status is considered to be an important prognostic factor regarding the long-term survival of breast cancer (BC) patients (Cetin IA, et al . 2020). The knowledge of whether lymph nodes are tumor-infiltrated or not is essential since nodal involvement has decisive therapeutic consequences such as axillary lymph node dissection (ALND), axillary radiotherapy, and neoadjuvant or adjuvant systemic chemotherapy (Diessner J et al . 2023). To provide individualized therapeutic options and optimized therapy.

NCT ID: NCT06185855 Not yet recruiting - Breast Cancer Clinical Trials

A Simplified Approach to Predicting the Malignancy of Breast Lesions: Nomogram in Ultrasonography

Start date: December 30, 2023
Phase:
Study type: Observational

This study aims to construct and validate a quantitative mammographic model based on breast ultrasound images, incorporating patient characteristics such as age and significant sonographic features. The model is intended for precise discrimination of breast lesions while assessing its diagnostic performance in clinical practice. Our goal is to provide a reliable adjunct tool to enhance the clinical decision-making of healthcare professionals and potentially improve early screening and accurate diagnosis of breast diseases.

NCT ID: NCT06185738 Not yet recruiting - Breast Cancer Clinical Trials

WeCanManage. An mHealth Self-management Tool

Start date: July 2024
Phase: N/A
Study type: Interventional

Examine the Feasibility, Acceptability, User Satisfaction, and Response Patterns and Preliminary Efficacy on Targeted Patient Reported Outcomes. Using a pre-post, single arm feasibility design with cancer survivors with disabilities

NCT ID: NCT06185569 Recruiting - Breast Cancer Clinical Trials

FREDO-ODX Study: FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guided Therapy

FREDO-ODX-23
Start date: October 15, 2023
Phase:
Study type: Observational

The aim of this study is to assess the clinical outcomes in real-life setting of early breast cancer RH+ HER2- patients with systemic therapy guided by Oncotype DX (ODX) Breast Recurrence Score®.

NCT ID: NCT06185205 Recruiting - Breast Cancer Clinical Trials

ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy

ASHBY
Start date: December 12, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare any good and bad effects of giving radiation treatment for breast cancer in 3 treatments over about 2 days.

NCT ID: NCT06184867 Recruiting - Breast Cancer Clinical Trials

Choices About Genetic Testing And Learning Your Risk With Smart Technology

CATALYST
Start date: October 26, 2023
Phase: Early Phase 1
Study type: Interventional

The goal of this observational study is to increase genetic education and genetic testing for hereditary cancer risk among cancer survivors. The study objectives are to: 1. Finalize the development and optimize usability of the CATALYST digital intervention (i.e., also known as relational assistant (RA)) 2. Evaluate the feasibility and acceptability of a streamlined cancer genomic care delivery model in cancer survivors. Participants will be randomized to one of two study arms: the RA intervention vs. enhanced usual care (EUC) 3. Assess GC and GT uptake and conduct a process evaluation to measure barriers/facilitators to GC, GT and use of the CATALYST intervention and engagement with the RA.

NCT ID: NCT06184750 Not yet recruiting - Breast Carcinoma Clinical Trials

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Start date: November 26, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer. Increasing breast density is a well established risk factor for breast cancer. Tamoxifen is a selective estrogen receptor modulator. It works by blocking the effects of the hormone estrogen in the breast. Tamoxifen has been shown to reduce breast density, even at reduced dosages, and is approved for the prevention of breast cancer.

NCT ID: NCT06184074 Recruiting - Breast Cancer Clinical Trials

Effect of Aromatase Inhibitors on Ultrasonographic Measurements and Static and Dynamic Balance Scores in Breast Cancer

Start date: February 1, 2024
Phase:
Study type: Observational

To evaluate the effects of aromatase inhibitors on lower extremity ultrasonographic measurements, static and dynamic balance scores in breast cancer patients using aromatase inhibitors